We are a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA […]

  We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat cancer. Our approach for cellular immunotherapy involves chimeric antigen receptors, or CARs, on the surface of an NK cell that enable the cell to recognize specific proteins or antigens that are present […]

  We will seek to acquire those businesses that are currently strategically significant in the Asian markets. Such sectors include: Internet and high technology, financial technology (including technology applied in financial services or used to help companies manage the financial aspects of their business), logistics, clean energy, health care, consumer and retail, energy and resources, […]

  We have historically focused on specialty risks within the casualty market, including specialty workers’ compensation insurance. While there is no official definition of specialty risks, the specialist component of the P&C market entails expertise in underwriting, loss control, claims and customer knowledge. Specialty insurance markets can focus on niche market segments or specific industries […]

  We are a leading health insurance marketplace whose mission is to improve access to healthcare in America. Our proprietary technology platform leverages modern machine-learning algorithms powered by nearly two decades of insurance behavioral data to reimagine the optimal process for helping individuals find the best health insurance plan for their specific needs. Our differentiated […]

(Note: No Call. This is a “firm commitment” unit offering of 1 million units. Each unit consists of one share of common stock and one warrant to buy one share of common stock. From the prospectus: “We intend to apply to list our shares of common stock and Warrants for trading on the Nasdaq Capital […]

  Our story started in the year 2000, when our founder, Mr. Baoli Ma, a closeted policeman by the alias “Geng Le,” founded one of China’s first and most influential LGBTQ online forums, Danlan.org. Danlan.org is the predecessor of BlueCity, and Mr. Ma is our number one employee.

  While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare industry, with an emphasis on the biotechnology […]

  We are a B2B e-commerce platform of automotive products and a supplier of auto perfume and auto air fresheners. Since our inception in 2004, we have been specializing in the development, manufacturing and sales of auto perfume and air fresheners. We also operate an online B2B marketplace of automotive products focusing on serving wholesale […]

  Our efforts to identify a target business will not be limited to a particular industry or geographic region, although we intend to focus on operating businesses in and around the high-tech industry in the United States.